Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03792555




Registration number
NCT03792555
Ethics application status
Date submitted
27/12/2018
Date registered
3/01/2019
Date last updated
16/07/2021

Titles & IDs
Public title
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
Scientific title
A Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients With Acromegaly That Are Responders to Octreotide LAR or Lanreotide Depot (ACROBAT Evolve)
Secondary ID [1] 0 0
2018-001833-42
Secondary ID [2] 0 0
CRN00808-02
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acromegaly 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other endocrine disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Paltusotine
Treatment: Drugs - Placebo

Experimental: Paltusotine -

Placebo Comparator: Placebo -


Treatment: Drugs: Paltusotine
Paltusotine, capsules, once daily by mouth

Treatment: Drugs: Placebo
Placebo, capsules, once daily by mouth
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of subjects who meet responder criteria (based on the mean of two consecutive insulin-like growth factor-1 [IGF-1] measurements = upper limit of normal [ULN])
Timepoint [1] 0 0
13 Weeks
Secondary outcome [1] 0 0
Change in IGF-1 levels
Timepoint [1] 0 0
From Week 10 to Week 13
Secondary outcome [2] 0 0
Change in growth hormone (GH) levels
Timepoint [2] 0 0
From Week 8 to Week 13
Secondary outcome [3] 0 0
Change in patient assessed symptoms of acromegaly
Timepoint [3] 0 0
From Week 10 to Week 13

Eligibility
Key inclusion criteria
1. Male and female subjects 18 to 70 years of age

2. Confirmed diagnosis of acromegaly that is controlled on stable doses of octreotide LAR
or lanreotide depot

3. Females must be non-pregnant and non-lactating, and either surgically sterile,
post-menopausal, or using effective method(s) of birth control

4. Willing to provide signed informed consent
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Treatment naïve acromegaly subjects

2. Prior treatment with paltusotine

3. Pituitary surgery within 6 months prior to Screening or radiation therapy at any time
prior to the study entry. Pituitary radiation therapy (within 3 to 4 years or more
than 4 years prior to study entry) with recently documented elevated IGF-1 may be
eligible.

4. History or presence of malignancy except adequately treated basal cell and squamous
cell carcinomas of the skin within the past 5 years.

5. Use of any investigational drug within the past 30 days or 5 half-lives, whichever is
longer

6. Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C
antibody (HCV-Ab) or has a history of a positive result

7. History of alcohol or substance abuse in the past 12 months

8. Any condition that in the opinion of the investigator would jeopardize the subject's
appropriate participation in this study

9. Cardiovascular conditions or medications associated with prolonged QT or those which
predispose subjects to heart rhythm abnormalities.

10. Subjects with symptomatic cholelithiasis

11. Subjects with clinically significant abnormal findings during the Screening Period,
and any other medical condition(s) or laboratory findings that, in the opinion of the
Investigator, might jeopardize the subject's safety or ability to complete the study

12. Subjects who have been taking the following prior medications: pegvisomant (within the
last 3 months), dopamine agonists (within the last 3 months) and pasireotide LAR
(within the last 6 months)

13. Subjects taking octreotide LAR at a dose higher than 40 mg or lanreotide depot at a
dose higher than 120 mg

14. Subjects who usually take octreotide LAR or lanreotide depot less frequently than
every 4 weeks (e.g. every 6 weeks or 8 weeks)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/12/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/08/2020
Sample size
Target
Accrual to date
Final
13
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Royal Brisbane & Women's Hospital - Herston
Recruitment hospital [3] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment hospital [4] 0 0
Keogh Institute for Medical Research - Nedlands
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Herston
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Oregon
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
Brazil
State/province [10] 0 0
Curitiba
Country [11] 0 0
Brazil
State/province [11] 0 0
Rio De Janeiro
Country [12] 0 0
Brazil
State/province [12] 0 0
São Paulo
Country [13] 0 0
Germany
State/province [13] 0 0
Munich
Country [14] 0 0
Germany
State/province [14] 0 0
München
Country [15] 0 0
Greece
State/province [15] 0 0
Athens
Country [16] 0 0
Greece
State/province [16] 0 0
Thessaloníki
Country [17] 0 0
Hungary
State/province [17] 0 0
Budapest
Country [18] 0 0
Hungary
State/province [18] 0 0
Pécs
Country [19] 0 0
Italy
State/province [19] 0 0
Milano
Country [20] 0 0
Italy
State/province [20] 0 0
Napoli
Country [21] 0 0
New Zealand
State/province [21] 0 0
Takapuna
Country [22] 0 0
New Zealand
State/province [22] 0 0
Wellington
Country [23] 0 0
Poland
State/province [23] 0 0
Krakow
Country [24] 0 0
Poland
State/province [24] 0 0
Kraków
Country [25] 0 0
Poland
State/province [25] 0 0
Warsaw
Country [26] 0 0
Romania
State/province [26] 0 0
Bucharest
Country [27] 0 0
Romania
State/province [27] 0 0
Cluj-Napoca
Country [28] 0 0
Serbia
State/province [28] 0 0
Belgrade
Country [29] 0 0
Serbia
State/province [29] 0 0
Novi Sad
Country [30] 0 0
Slovakia
State/province [30] 0 0
Bratislava
Country [31] 0 0
Slovakia
State/province [31] 0 0
Lubochna
Country [32] 0 0
United Kingdom
State/province [32] 0 0
Coventry
Country [33] 0 0
United Kingdom
State/province [33] 0 0
Leeds
Country [34] 0 0
United Kingdom
State/province [34] 0 0
London
Country [35] 0 0
United Kingdom
State/province [35] 0 0
Manchester
Country [36] 0 0
United Kingdom
State/province [36] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Crinetics Pharmaceuticals Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to
evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808; an
oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with
acromegaly that are responders to octreotide LAR or lanreotide depot.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03792555
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03792555